41 completed, 11 terminated, 4 unknown, 3 withdrawn. 20 Phase 3, 19 Phase 2, 10 Phase 4, 8 Not applicable, 8 Phase 1.
Follow ambrisentan: new trials by email Literature Review of ambrisentan trials Research Report on ambrisentan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular Comorbidities Tadalafil, Ambrisentan, Placebo (Ambrisentan-matching) - Pulmonary Arterial Hypertension (PAH), Comorbidities | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 186 | 2026-04-28 | 2026-05-13 |
| Ambrisentan for Early Low-Risk Pulmonary Arterial Hypertension Ambrisentan, Placebo - Pulmonary Arterial Hypertension (PAH) | Not applicable | Not yet recruiting | Nanjing First Hospital, Nanjing Medical University | 410 | 2025-05-15 | 2025-05-23 |
| Comparison of Sequential to Initial Combination Therapy in PAH Tadalafil, Ambrisentan, Ambrisentan mimic - Pulmonary Arterial Hypertension (PAH) | Not applicable | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 376 | 2025-05-14 | 2025-07-29 |
| Endothelin Receptor Antagonism With Ambrisentan to Treat Hepatorenal Syndrome Ambrisentan, Terlipressin - Hepatorenal Syndrome, Liver Cirrhosis | Phase 2 | Active not recruiting | Noorik Biopharmaceuticals AG | 54 | 2024-04-17 | 2026-04-13 |
| Treatment With Ambrisentan in Patients With Borderline Pulmonary Arterial Hypertension Ambrisentan, Placebo - Pulmonary Arterial Hypertension | Not applicable | Unknown | Nanjing First Hospital, Nanjing Medical University | 420 | 2022-09-05 | 2022-09-28 |
| Early Postoperative Triple Targeted Therapy in Patients With CHD-PAH in the "Grey Zone" Control group (ambrisentan plus tadalafil or macitentan plus tadalafil), Treatment group (ambrisentan plus tadalafil plus treprostinil or macitentan plus tadalafil plus treprostinil) - Congenital Heart Disease, Pulmonary Hypertension | Not applicable | Completed | China National Center for Cardiovascular Diseases | 30 | 2022-08-25 | 2026-09-28 |
| A Study of Micro Dose Ambrisentan in Hospitalized Patients With Respiratory Insufficiency Due to COVID-19 Ambrisentan, Placebo - Covid19, Hypoxemia | Phase 2 | Terminated | Noorik Biopharmaceuticals AG | 88 | 2021-02-08 | 2023-03-21 |
| Pilot Study of the Safety and Efficacy of Sulfasalazine in Pulmonary Arterial Hypertension Sulfasalazine, Ambrisentan, Sulfasalazine's placebo - Pulmonary Arterial Hypertension | Phase 1 / Phase 2 | Unknown | RenJi Hospital | 80 | 2020-08-01 | 2020-08-27 |
| mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms EDP1815, Dapagliflozin, Ambrisentan - COVID-19 | Phase 2 / Phase 3 | Completed | Cambridge University Hospitals NHS Foundation Trust | 454 | 2020-07-03 | 2023-07-28 |
| A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver Cirrhosis Ambrisentan - Cirrhosis, Portal Hypertension | Phase 2 | Terminated | Noorik Biopharmaceuticals AG | 19 | 2019-04-11 | 2021-02-26 |
| Efficacy and Safety Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension Ambrisentan - Pulmonary Arterial Hypertension | Phase 3 | Completed | RenJi Hospital | 80 | 2018-12-18 | 2022-06-29 |
| Effects of Endothelin Receptor Antagonist on Ischemic Kidney Injury During Nephron Sparing Surgery Ambrisentan 10 MG - Kidney Failure, Acute | Phase 2 | Unknown | Bnai Zion Medical Center | 30 | 2018-10-11 | 2020-06-29 |
| Efficacy and Safety of Combination Ambrisentan and Tadalafil in Patients With Portopulmonary Hypertension Ambrisentan Pill, Tadalafil Pill - Portopulmonary Hypertension, Pulmonary Hypertension | Phase 4 | Withdrawn | Ochsner Health System | 2017-10-12 | 2018-12-07 | |
| Mechanisms of Cerebrovascular Control NOS Inhibition, ET-1 Inhibition, NOS Inhibition Placebo - Metabolic Syndrome X | Phase 1 | Completed | University of Wisconsin, Madison | 59 | 2017-01-31 | 2021-10-18 |
| Crossover Study From Macitentan or Bosentan Over to Ambrisentan Ambrisentan - Pulmonary Arterial Hypertension | Phase 4 | Terminated | Medical University of South Carolina | 3 | 2016-06-01 | 2019-04-08 |
| A Phase 1 Relative Bioavailability Study of Ambrisentan and Tadalfil Fixed Dose Combination Tablets in Healthy Subjects FDC (ambrisentan 10 mg-tadalafil 40 mg) single dose, Reference (ambrisentan 10 mg + tadalafil 40 mg given concurrently) - Hypertension, Pulmonary | Phase 1 | Completed | GlaxoSmithKline | 112 | 2016-03-18 | 2019-01-22 |
| The Role of Endothelin-1 in Sickle Cell Disease Ambrisentan, Placebo - Sickle Cell Anemia | Phase 1 | Completed | Augusta University | 26 | 2015-09-01 | 2020-04-02 |
| The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study Ambrisentan plus Spironolactone, Ambrisentan plus Placebo - Pulmonary Arterial Hypertension | Phase 4 | Terminated | Brigham and Women's Hospital | 2 | 2015-09-01 | 2019-11-15 |
| Ambrisentan in Single Ventricle Ambrisentan, Placebo - Hypoplastic Left Heart Syndrome, Hypoplastic Right-sided Heart Complex | Phase 2 | Completed | Kevin Hill | 16 | 2015-07-01 | 2019-09-12 |
| Early Treatment of Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (SSc-APAH) Ambrisentan, Placebo - Systemic Sclerosis, Pulmonary Hypertension | Phase 2 | Completed | Heidelberg University | 38 | 2014-07-01 | 2020-04-30 |
Showing 20 of 63. Sign in to see all of them.
Hypertension, Pulmonary (24) · Pulmonary Arterial Hypertension (24) · Scleroderma, Systemic (5) · Acute Kidney Injury (2) · Altitude Sickness (2) · COVID-19 (2) · Connective Tissue Diseases (2) · Dyspnea (2) · Esophageal and Gastric Varices (2) · Familial Primary Pulmonary Hypertension (2) · Hypertension (2) · Hypertension, Portal (2) · Idiopathic Pulmonary Fibrosis (2) · Liver Cirrhosis (2) · Anemia, Sickle Cell (1)
Gilead Sciences (12) · GlaxoSmithKline (12) · Noorik Biopharmaceuticals AG (3) · Brigham and Women's Hospital (2) · Medical University of South Carolina (2) · Nanjing First Hospital, Nanjing Medical University (2) · RenJi Hospital (2) · Assistance Publique - Hôpitaux de Paris (1) · Augusta University (1) · Bnai Zion Medical Center (1) · Cambridge University Hospitals NHS Foundation Trust (1) · Center for Health Sciences, Serbia (1) · China National Center for Cardiovascular Diseases (1) · Heidelberg University (1) · Johns Hopkins University (1)
United States (35) · Germany (10) · Canada (9) · Spain (9) · United Kingdom (9) · Australia (8) · China (8) · Argentina (7) · France (7) · Italy (7) · Japan (7) · Austria (6) · Mexico (5) · Netherlands (5) · Russia (5)
Jieyan Shen, PhD (2) · Aaron Waxman, MD, PhD (1) · Abdullah Kutlar, MD (1) · Bradley Maron, MD (1) · Brett Fenster, MD (1) · Chris Derk, MD, MSc (1) · Chris Dufton, PhD (1) · Claude A Piantadosi, MD (1) · Dinesh Khanna, MD (1) · Don C Rockey, MD (1) · Fernando Torres, MD (1) · Ganesh Raghu, MD (1)
PMID 18506008, PMID 18812445, PMID 19909879, PMID 22506623, PMID 22777623, PMID 23648946, PMID 24177001, PMID 24342407, PMID 24717624, PMID 25613108, PMID 25876611, PMID 26196225, PMID 26308684, PMID 26360334, PMID 27683610, PMID 27770771, PMID 28039187, PMID 29251556, PMID 29282676, PMID 30886964, PMID 31060740, PMID 31511080, PMID 31655622, PMID 32008947, PMID 32161055, PMID 32680480, PMID 32736592, PMID 32799568, PMID 34473343, PMID 36579617, PMID 37254256, PMID 37332660, PMID 37378404, PMID 41653169
2018 (1), 2023 (1), P50HL084946 (1), U01HL117684 (1)